目的 合并肺纤维化的慢性阻塞性肺疾病（COPD）是COPD的特殊亚型，患者兼具气流受限与肺组织纤维化病理特征，临床症状更严重、肺功能下降更快，且现有单一治疗方案难以同时改善气流受限与纤维化进展，预后较差。基于此，本研究旨在分析尼达尼布联合格隆溴铵治疗合并肺纤维化的COPD患者的效果及对肺功能的影响，为优化临床治疗方案提供依据。方法 选取2022年3月—2024年12月收治的96例合并肺纤维化的COPD患者，采用前瞻性随机对照研究设计，应用随机数字表法分为试验组与对照组。所有患者均采取常规治疗，对照组48例采取尼达尼布治疗，试验组采取尼达尼布联合格隆溴铵治疗。两组均治疗24周后，比较治疗前后症状评分、肺功能、纤维化指标、炎症指标，并分析两组治疗安全性。结果 治疗后，两组CAT评分、mMRC评分及VAS降低（P＜0.05）；且与对照组比较，试验组CAT评分、mMRC评分及咳嗽VAS评分较低（P＜0.05）。治疗后，两组FVC、FEV₁、DLCO及FEV₁/FVC比值均较治疗前改善（P＜0.05）；且与对照组比较，试验组FVC、FEV₁、DLCO及FEV₁/FVC比值较优（P＜0.05）。治疗后，两组血清KL-6、SP-D水平及CT纤维化评分均降低（P＜0.05）；且与对照组比较，试验组血清KL-6、SP-D水平及CT纤维化评分较低（P＜0.05）。治疗后，两组血清IL-6、TNF-α及TGF-β1水平降低（P＜0.05）；且与对照组比较，试验组血清IL-6、TNF-α及TGF-β1水平较低（P＜0.05）。试验组总不良反应发生率为8.33%（4/48），对照组为10.42%（5/48），两组比较差异无统计学意义（P＞0.05）。结论 尼达尼布联合格隆溴铵治疗合并肺纤维化的COPD效果良好，可减轻患者临床症状，改善肺功能与肺纤维化，降低机体炎症反应，安全性较高。

   Objective To analyze the effects of the combination of nintedanib and glycopyrrolate in treating chronic obstructive pulmonary disease（COPD）patients with associated pulmonary fibrosis and its impact on lung function，providing a basis for optimizing clinical treatment strategies．Methods Ninety-six COPD patients with pulmonary fibrosis admitted from March 2022 to December 2024 were selected，and divided into experimental group and control group using a random number table method．Using a prospective randomized controlled study design，all patients received conventional treatment，with 48 cases in the control group receiving treatment with nintedanib and the experimental group receiving treatment with nintedanib combined with glycopyrrolate bromide．After 24 weeks of treatment in both groups，the symptom scores，lung function，fibrosis indicators，and inflammation indicators were compared before and post-treatment，and the drug safety of the two groups was analyzed．Results Post-treatment，CAT score，mMRC score and VAS decreased in both groups（P＜0.05）．Compared with the control group，CAT score，mMRC score and cough VAS score were lower in the experimental group（P＜0.05）．Post-treatment，FVC，FEV₁，DLCO and FEV₁/FVC ratio of both groups improved compared with that before treatment（P＜0.05）．Compared with the control group，FVC，FEV₁，DLCO and FEV₁/FVC ratio of the experimental group were better（P＜0.05）．Post-treatment，serum KL-6，SP-D levels and CT fibrosis scores of both groups decreased（P＜0.05）．Compared with the control group，serum KL-6，SP-D levels and CT fibrosis scores of the experimental group were lower（P＜0.05）．Post-treatment，serum IL-6，TNF-α and TGF-β1 levels in both groups decreased（P＜0.05）．Compared with the control group，serum IL-6，TNF-α and TGF-β1 levels in the experimental group were lower（P＜0.05）．The incidence of total adverse reactions in the experimental group was 8.33%（4/48），and that in the control group was 10.42%（5/48）．There was no difference between the two groups（P＞0.05）．Conclusions The combination of nintedanib and glycopyrrolate has a significant effect on the treatment of COPD complicated with pulmonary fibrosis，which can alleviate its clinical symptoms，improve lung function and pulmonary fibrosis，reduce the body’s inflammatory response，which is relatively safe．

目的 分析中药穴位贴敷、沙库巴曲缬沙坦联合治疗在慢性心力衰竭（CHF）中的应用效果。方法 选取我院CHF患者90例（2024-08—2026-01），依据随机数字表分成两组，每组45例。对照组接受沙库巴曲缬沙坦治疗，研究组接受中药穴位贴敷联合沙库巴曲缬沙坦治疗。观察两组疗效、6min步行距离、中医证候积分、心功能[心脏指数（CI）、每搏输出量（SV）、左室射血分数（LVEF）]、心肌指标[脑钠肽（BNP）、肌钙蛋白Ⅰ（cTnⅠ）]、安全性。结果 研究组治疗效果优于对照组（P＜0.05）；治疗后，研究组中医证候积分、BNP、cTnⅠ低于对照组，6min步行距离、LVEF、CI、SV高于对照组（P＜0.05）；两组治疗期间不良反应无显著差异（P＞0.05）。结论 中药穴位贴敷联合沙库巴曲缬沙坦治疗CHF效果显著，可减轻临床症状，改善心功能，减少心肌损伤。

Objective To analyze the clinical efficacy of combined therapy with traditional Chinese medicine acupoint application and sacubitril/valsartan in patients with chronic heart failure (CHF). Methods A total of 90 patients with CHF admitted to our Hospital from August 2024 to January 2026 were selected, and divided into two groups by random number table, with 45 cases in each group. The control group was treated with sacubitril/valsartan, while the study group received combined therapy of traditional Chinese medicine acupoint application and sacubitril/valsartan. The therapeutic efficacy, 6-minute walking distance, TCM syndrome score, cardiac function indexes [cardiac index (CI), stroke volume (SV), left ventricular ejection fraction (LVEF)], myocardial indicators [brain natriuretic peptide (BNP), cardiac troponin Ⅰ (cTnⅠ)] and safety were observed in both groups. Results The therapeutic efficacy of the study group was better than that of the control group (P<0.05). After treatment, the TCM syndrome scores, BNP and cTnⅠ levels in the observation group were lower, while the 6-minute walking distance, LVEF, CI and SV were higher compared with the control group (P<0.05). No significant between-group difference was found in adverse reactions during treatment (P>0.05). Conclusion Traditional Chinese medicine acupoint application combined with sacubitril/valsartan achieves remarkable efficacy in the treatment of CHF. It can relieve clinical symptoms, improve cardiac function and alleviate myocardial injury.

目的 探究子午流注择时中药灌肠联合腹内压分级导向的早期肠内营养（EEN）护理方案对脓毒症胃肠功能障碍患者的影响。方法 选取92例脓毒症胃肠功能障碍患者，均在2025年1月～2026年2月收治于本院，按随机数字表法分为两组，各46例。对照组行腹内压分级导向的EEN护理，观察组在此基础上加用子午流注择时中药灌肠。对比两组中医证候积分、急性生理学与慢性健康状况评分Ⅱ（APACHEⅡ）、胃肠功能障碍评分（GIDS）、腹内压、喂养不耐受、7d内目标喂养量达成率、28d病死率。结果 干预7d，两组中医证候积分、APACHEⅡ评分、GIDS评分及腹内压均降低，观察组较低（P＜0.05）。观察组7d内目标喂养量达成率较高，喂养不耐受率较低（P＜0.05）。两组28d病死率无差异（P＞0.05）。结论 子午流注择时中药灌肠联合腹内压分级导向的EEN护理可以改善脓毒症胃肠功能障碍患者的健康状况与喂养情况，减轻胃肠功能障碍症状，降低腹内压，未显著降低28d病死率。

目的 探讨寒湿痹颗粒联合柳氮磺吡啶对强直性脊柱炎（AS）患者临床疗效、症状程度、脊柱功能、炎性因子、趋化因子的影响。方法 选取我院2023年7月-2025年6月收治的114例AS患者作为研究对象，依据随机数字表分成两组，每组57例。西药组行柳氮磺吡啶治疗，中药联合组行寒湿痹颗粒联合柳氮磺吡啶治疗。治疗3个月后，比较两组疗效、症状程度[Bath强直性脊柱炎疾病活动指数（BASDAI）]、脊柱功能[Bath强直性脊柱炎功能指数（BASFI）、Bath强直性脊柱炎计量学指数（BASMI）]、炎症因子[白介素-1β（IL-1β）、肿瘤坏死因子-α（TNF-α）]、趋化因子[胸腺活化调节趋化因子（TARC）、干扰素γ诱导蛋白10（IP-10）]及不良反应。结果 治疗3个月后，中药联合组治疗有效率为94.74%，高于西药组的78.95%（P＜0.05）；中药联合组BASDAI评分、BASFI评分、BASMI评分、血清IL-1β、TNF-α、TARC、IP-10水平均低于西药组（P＜0.05）；治疗期间，中药联合组不良反应发生率为7.02%，与西药组的3.51%比较，无显著差异（P＞0.05）。结论 寒湿痹颗粒联合柳氮磺吡啶治疗AS患者效果显著，能有效改善临床症状，抑制炎性反应，改善趋化因子水平，促进脊柱功能恢复，且具有较高的用药安全性。

目的 探究基于卡诺模型的阶段性康复护理对脑梗死后偏瘫患者心理状态及肢体功能的影响。 方法 本研究回顾性纳入2024年3月—2025年3月我院收治的86例脑梗死后偏瘫患者，并按护理方案差异将其均分为观察组与对照组，每组各43例。对照组采用采用常规康复护理方案，观察组在此基础上采用基于卡诺模型的阶段性康复护理。干预后，统计对比两组心理状态[汉密尔顿焦虑量表（HAMA）、汉密尔顿抑郁量表（HAMD）]、神经功能[美国国立卫生研究院卒中量表(NIHSS)]、自我管理能力[中文版脑卒中自我管理能力量表(SSSMQ)]、日常生活能力[改良Barthel指数（MBI）]、肢体功能[Fugl-Meyer运动功能积分法（FMA）]、康复依从性、护理满意度。结果 干预后，观察组HAMA、HAMD评分均显著低于对照组，FMA各维度及总分均显著高于对照组（P＜0.05）；干预后，观察组NIHSS评分低于对照着，SSSMQ、MBI评分高于对照组（P＜0.05）；观察组治疗总依从率显著高于对照组，护理总满意度显著高于对照组（P＜0.05）。结论 基于卡诺模型的阶段性康复护理应用于脑梗死后偏瘫患者，能改善其心理状态，提高康复依从性及自我管理能力，有助于改善患者神经功能，增强肢体功能，恢复生活活动能力，提高护理满意度。

目的 探讨桑白皮汤加减辅助常规西药治疗痰热郁肺型保留比率的肺功能减损（PRISm）患者的治疗效果，并分析其对中医证候积分、肺功能、气道阻力、免疫功能的影响。方法 选取2024年6月～2025年6月于本院诊治的88例PRISm患者为研究对象，按照随机数字表法将其分为对照组（常规西药治疗）、研究组（桑白皮汤加减联合常规西药治疗），各44例。比较两组临床疗效、不良反应及治疗前后中医证候积分、慢阻肺评估测试（CAT）量表、改良版英国医学研究委员会呼吸困难问卷（mMRC）、吸入支气管扩张剂后检测肺功能、肺弥散功能[一氧化碳弥散量占预计值百分比（DLCO%pred）、残气量/肺总量（RV/TLC）]、气道阻力[抗阻指数（R5-20）、共振频率（Fres）、呼吸总阻抗（Zrs）]、炎症指标[白细胞介素-6（IL-6）、可溶性细胞间黏附分子-1（sICAM-1）、单核细胞趋化蛋白-1（MCP-1）、嗜酸性粒细胞（EOS）、肿瘤坏死因子-α（TNF-α）]、气道重塑[基质金属蛋白酶-2（MMP-2）、缺氧诱导因子-1α（HIF-1α）、转化生长因子-β1（TGF-β1）、碱性成纤维细胞生长因子（bFGF）]、T淋巴细胞亚群水平。结果 研究组总有效率高于对照组（P＜0.05）；治疗后，与对照组比较，研究组中医证候积分、CAT评分、mMRC评分级RV/TLC降低，FEV1、FEV1/FVC、FEV1%pred、VC%pred、DLCO%pred升高（P＜0.05）；治疗后，与对照组比较，研究组R5-20、Fres、Zrs降低（P＜0.05）；治疗后，与对照组比较，研究组血清IL-6、sICAM-1、MCP-1、EOS、TNF-α及MMP-2、HIF-1α、TGF-β1、bFGF水平降低（P＜0.05）；治疗后，与对照组比较，研究组CD3+、CD4+、CD4+/CD8+水平升高（P＜0.05）；两组不良反应比较无明显差异（P＞0.05）。结论 桑白皮汤加减辅助常规西药治疗PRISm患者的疗效显著，可改善临床症状、肺功能，提高生活质量，降低气道阻力，并可减轻炎症反应，缓解气道重塑，增强机体免疫功能，且具有一定安全性。

【摘要】目的 探讨脊柱侧弯术后胃肠道功能紊乱患者“温通调补”理论指导下火龙罐综合灸的应用价值。方法 选取2025年6月-2026年6月本院收治的86例脊柱侧弯术后胃肠道功能紊乱患者作为研究对象，采用Excel软件随机函数分为对照组与观察组，每组各43例，评估患者胃肠道功能恢复时间、POGD、中医证候评分、PAC-QOL评分、VAS评分、胃肠道菌群数及胃激素指标水平。结果 治疗后，对照组的肠鸣音恢复时间、首次排气时间、首次排便时间均显著多于观察组（P＜0.05）；对照组的VAS评分、POGD评分、PAC-QOL评分及中医证候评分均显著高于观察组（P＜0.05）；对照组的乳酸杆菌及双歧杆菌数均显著低于观察组（P＜0.05），肠球菌及肠杆菌数均显著高于观察组（P＜0.05）；对照组的VIP水平均显著高于观察组（P＜0.05），MTL、GAS水平均显著低于观察组（P＜0.05）。结论 “温通调补”理论指导下火龙罐综合灸可有效改善患者脊柱侧弯术后胃肠道功能紊乱，调节其肠道菌群、胃肠道激素水平，缓解疼痛，提高患者生活质量。

目的：探讨基于超声实时引导的精准骶管阻滞联合喉罩全麻对阴式子宫切除手术患者术中应激反应及术后肠功能恢复的影响。方法：本研究采用前瞻性、单中心随机对照试验，选取2023年1月至2025年1月于我院择期行阴式子宫切除术的患者108例，随机分为对照组（n=54）和观察组（n=54）。对照组行单纯喉罩全身麻醉，观察组行超声实时引导精准骶管阻滞（0.25%罗哌卡因20 mL）联合喉罩全身麻醉。比较两组患者术中不同时间点血流动力学指标[平均动脉压（MAP）、心率（HR）]、应激反应指标[血清皮质醇（COR）、去甲肾上腺素（NE）、血糖（GLU）]、术后肠功能恢复指标（肠鸣音恢复时间、首次排便时间、首次排气时间）、术后疼痛视觉模拟评分（VAS）、术后镇痛泵有效按压次数、补救镇痛率及不良反应发生率。主要结局指标为术后24 h VAS评分，次要结局指标包括术中应激反应指标和术后肠功能恢复指标。结果：两组患者年龄、BMI、手术时间及术中出血量比较，差异均无统计学意义（P>0.05）。与T0时点比较，两组T1、T2、T3时点MAP、HR均升高，但观察组T1、T2、T3时点MAP、HR均低于对照组（P<0.05）。两组T1、T2、T3时点COR、NE、GLU水平均高于T0时点，但观察组T1、T2、T3时点COR、NE、GLU水平均低于对照组（P<0.05）。观察组术后肠鸣音恢复时间、首次排便时间及首次排气时间均短于对照组（P<0.05）。观察组术后2 h、6 h、12 h、24 h VAS评分均低于对照组（P<0.05），术后镇痛泵有效按压次数及补救镇痛率均低于对照组（P<0.05）。观察组术后恶心呕吐（PONV）发生率低于对照组（P<0.05），两组尿潴留发生率比较差异无统计学意义（P>0.05）。结论：基于超声实时引导的精准骶管阻滞联合喉罩全麻可有效减轻阴式子宫切除手术患者术中应激反应，维持血流动力学稳定，促进术后肠功能恢复，提高术后镇痛质量，且不增加不良反应发生率，值得临床推广应用。

Objective: To investigate the effects of ultrasoundguided realtime precise caudal block combined with laryngeal mask airway (LMA) general anesthesia on intraoperative stress response and postoperative bowel function recovery in patients undergoing vaginal hysterectomy. Methods: This prospective, singlecenter randomized controlled trial enrolled 108 patients who underwent elective vaginal hysterectomy in our hospital from January 2023 to January 2025. They were randomly divided into a control group (n=54) and an observation group (n=54). The control group received LMA general anesthesia alone, while the observation group received ultrasoundguided realtime precise caudal block (0.25% ropivacaine 20 mL) combined with LMA general anesthesia. The following parameters were compared between the two groups: hemodynamic variables [mean arterial pressure (MAP), heart rate (HR)] at different intraoperative time points, stress response indicators [serum cortisol (COR), norepinephrine (NE), blood glucose (GLU)], postoperative bowel function recovery indicators (time to bowel sound recovery, time to first defecation, time to first flatus), postoperative pain Visual Analog Scale (VAS) scores, effective pressing times of patientcontrolled analgesia (PCA) pump, rescue analgesia rate, and incidence of adverse reactions. The primary outcome was the 24 h postoperative VAS score; secondary outcomes included intraoperative stress response indicators and postoperative bowel function recovery indicators. Results: No significant differences were found between the two groups in age, BMI, operative time, or intraoperative blood loss (P>0.05). Compared with T0, MAP and HR at T1, T2 and T3 were increased in both groups, but the MAP and HR at T1, T2 and T3 in the observation group were significantly lower than those in the control group (P<0.05). Levels of COR, NE and GLU at T1, T2 and T3 were higher than those at T0 in both groups, but the levels in the observation group were significantly lower than those in the control group at the corresponding time points (P<0.05). The time to bowel sound recovery, time to first defecation and time to first flatus in the observation group were significantly shorter than those in the control group (P<0.05). The VAS scores at 2 h, 6 h, 12 h and 24 h postoperatively in the observation group were significantly lower than those in the control group (P<0.05); the effective pressing times of PCA pump and the rescue analgesia rate in the observation group were also significantly lower than those in the control group (P<0.05). The incidence of postoperative nausea and vomiting (PONV) in the observation group was significantly lower than that in the control group (P<0.05), whereas no significant difference was observed in the incidence of urinary retention between the two groups (P>0.05). Conclusion: Ultrasoundguided realtime precise caudal block combined with LMA general anesthesia can effectively alleviate intraoperative stress response, maintain hemodynamic stability, promote postoperative bowel function recovery, and improve postoperative analgesia quality in patients undergoing vaginal hysterectomy, without increasing the incidence of adverse reactions. Therefore, this combined anesthesia technique is worthy of clinical application.

目的 探究调阴和阳针法联合Bobath疗法对中风后痉挛性瘫痪（spastic paralysis after stroke，SPAS）患者痉挛程度及运动功能的影响。方法 回顾性选取2024年2月至2026年2月就诊于我院的102例SPAS患者，按照治疗方案分为对照组、研究组，各51例。对照组采用Bobath疗法治疗，研究组采用调阴和阳针法联合Bobath疗法治疗，均治疗4周。比较两组临床疗效、治疗前后中医证候积分、肢体痉挛程度[改良Ashworth分级（MAS）]、相关量表[Fugl－Meyer运动功能量表（FMA）、功能独立性量表（FIM）、Berg平衡量表（BBS）、改良Barthel指数（MBI）]评分、不良反应发生情况。结果 研究组愈显率、总有效率均高于对照组（P＜0.05）；研究组治疗4周后半身不遂、头晕目眩、肢体麻木或手足拘急、舌强言謇、口舌歪斜积分低于对照组（P＜0.05）；研究组治疗4周后MAS评分低于对照组（P＜0.05）；研究组治疗4周后FMA、FIM、BBS、MBI评分高于对照组（P＜0.05）；两组均无严重不良反应发生。结论 采用调阴和阳针法联合Bobath疗法联合治疗SPAS患者可有效减轻临床症状及痉挛程度，提高疗效，且有利于促进患者运动功能、平衡能力及生活能力恢复，安全性良好。

目的：探讨维生素B2（VB2）联合蓝光照射对新生儿黄疸康复进程及肝脏功能的影响。方法：选取2024年5月—2025年10月收治的150例黄疸患儿，应用随机数字表法分为常规组和试验组，每组75例。常规组接受蓝光照射治疗，试验组在常规组基础上口服VB2治疗。比较两组患儿的氧化应激反应[谷胱甘肽过氧化物酶（GSH-Px），8羟基脱氧鸟苷（8-OHdG）、晚期蛋白氧化产物（AOPP）、超氧阴离子（O2-）]、肝脏微循环[血管性血友病因子（vWF）、可溶性血栓调节蛋白（sTM）、肝动脉阻力指数（HA-RI）、门静脉血流速度（PVV）]、胆红素排泄[总胆红素（TBil）、间接胆红素（IBil）]、肝脏功能[丙氨酸氨基转移酶（ALT）、天门冬氨酸氨基转移酶（AST）]、康复进程[光疗时间、胆红素恢复正常时间、黄疸消退时间、住院康复时间]及治疗安全性。结果：治疗后，试验组的GSH-Px高于常规组，8-OHdG、AOPP、O2-均低于常规组（P＜0.05）；试验组的vWF、sTM、HA-RI均低于常规组，PVV高于常规组（P＜0.05）。试验组的TBil、IBil、ALT、AST分别为（80.52±5.47）μmol/L、（68.52±5.49）μmol/L、（30.25±5.48）U/L、（32.14±5.22）U/L，均低于常规组[（85.19±6.44）μmol/L、（74.37±6.52）μmol/L、（35.29±6.17）U/L、（38.55±6.48）U/L]，差异有统计学意义（P＜0.05）。试验组的光疗时间、胆红素恢复正常时间、黄疸消退时间、住院康复时间分别为（3.05±0.33）d、（4.22±1.39）d、（5.41±1.27）d、（5.12±0.49）d，均低于常规组[（3.68±0.36）d、（5.36±1.45）d、（6.28±1.33）d、（6.51±0.54）d]，差异有统计学意义（P＜0.05）。试验组的不良反应发生率与常规组比较，差异无统计学意义（P＞0.05）。结论：VB2联合蓝光照射可减轻黄疸患儿的氧化应激反应并改善肝脏微循环，对促进胆红素排泄、改善肝脏功能均有积极影响，在促进患儿康复同时未显著增加治疗风险。其安全性较高，可进一步推广。

Objective: To investigate the effects of vitamin B2 (VB2) combined with blue light irradiation on the recovery process and liver function of neonatal jaundice. Method: 150 children with jaundice admitted from May 2024 to October 2025 were selected and randomly divided into a control group and an experimental group using a random number table method, with 75 cases in each group. The conventional group received blue light irradiation treatment, while the experimental group received oral VB2 treatment on the basis of the conventional group. Compare the oxidative stress response of two groups of children [glutathione peroxidase (GSH Px) higher than the control group, 8-hydroxydeoxyguanosine (8-OHdG), advanced protein oxidation products (AOPP), superoxide anion (O2-)], liver microcirculation [von Willebrand factor (vWF), soluble thrombomodulin (sTM), hepatic artery resistance index (HA-RI), portal vein blood flow velocity (PVV)], bilirubin excretion [total bilirubin (TBil), indirect bilirubin (IBil)], liver function [alanine aminotransferase (ALT), aspartate aminotransferase (AST)], rehabilitation process [phototherapy time, bilirubin recovery time to normal, jaundice regression time]. Hospitalization rehabilitation time and treatment safety. Result: After treatment, the GSH Px levels in the experimental group were higher than those in the control group, while 8-OHdG, AOPP, and O2- levels were lower than those in the control group (P<0.05); The vWF, sTM, and HA-RI of the experimental group were lower than those of the control group, while PVV was higher than that of the control group (P<0.05). The TBil, IBil, ALT, and AST of the experimental group were (80.52 ± 5.47) μ mol/L, (68.52 ± 5.49) μ mol/L, (30.25 ± 5.48) U/L, and (32.14 ± 5.22) U/L, respectively, which were lower than those of the conventional group [(85.19 ± 6.44) μ mol/L, (74.37 ± 6.52) μ mol/L, (35.29 ± 6.17) U/L, (38.55 ± 6.48) U/L], and the difference was statistically significant (P<0.05). The phototherapy time, bilirubin recovery time, jaundice resolution time, and hospital rehabilitation time of the experimental group were (3.05 ± 0.33) days, (4.22 ± 1.39) days, (5.41 ± 1.27) days, and (5.12 ± 0.49) days, respectively, which were lower than those of the conventional group [(3.68 ± 0.36) days, (5.36 ± 1.45) days, (6.28 ± 1.33) days, and (6.51 ± 0.54) days], and the difference was statistically significant (P<0.05). The incidence of adverse reactions in the experimental group was not significantly different from that in the control group (P>0.05). Conclusion: VB2 combined with blue light irradiation can alleviate oxidative stress response and improve liver microcirculation in children with jaundice. It has a positive effect on promoting bilirubin excretion and improving liver function, and does not significantly increase treatment risk while promoting the recovery of children. It has high safety and can be further promoted.